Last reviewed · How we verify
Puumala Vaccine
At a glance
| Generic name | Puumala Vaccine |
|---|---|
| Sponsor | U.S. Army Medical Research and Development Command |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Combination HTNV and PUUV DNA Vaccine (PHASE1)
- Safety and Immunogenicity of a Hantaan Virus DNA Vaccine and a Puumala Virus DNA Vaccine, For The Prevention of Hemorrhagic Fever With Renal Syndrome (PHASE2)
- A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Puumala Virus DNA Vaccine (PHASE1)
- Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever (PHASE2)
- Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Puumala Vaccine CI brief — competitive landscape report
- Puumala Vaccine updates RSS · CI watch RSS
- U.S. Army Medical Research and Development Command portfolio CI